

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

ENTERED

1 <110> APPLICANT: Abbott Laboratories  
 2 Henkin, Jack  
 3 Haviv, Fortuna  
 4 Bradley, Michael F.  
 5 Kalvin, Douglas M.  
 6 Schneider, Andrew J.  
 7 <120> TITLE OF INVENTION: PEPTIDE ANTIANGIOGENIC DRUGS  
 8 <130> FILE REFERENCE: 6356.US.P4  
 9 <140> CURRENT APPLICATION NUMBER: US/09/833,196  
 10 <141> CURRENT FILING DATE: 2001-04-11  
 11 <150> PRIOR APPLICATION NUMBER: US 09/316,888  
 12 <151> PRIOR FILING DATE: 1999-05-21  
 13 <150> PRIOR APPLICATION NUMBER: US 60/126,546  
 14 <151> PRIOR FILING DATE: 1999-03-26  
 15 <150> PRIOR APPLICATION NUMBER: US 60/086,536  
 16 <151> PRIOR FILING DATE: 1998-05-22  
 17 <160> NUMBER OF SEQ ID NOS: 6  
 18 <170> SOFTWARE: FastSEQ for Windows Version 4.0  
 20 <210> SEQ ID NO: 1  
 21 <211> LENGTH: 10  
 22 <212> TYPE: PRT  
 23 <213> ORGANISM: Artificial Sequence  
 24 <220> FEATURE:  
 25 <223> OTHER INFORMATION: Antiangiogenetic Peptide  
 26 <221> NAME/KEY: VARIANT  
 27 <222> LOCATION: (1)...(1)  
 28 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Gln, Glu, NetGly, Met,  
 29 N-methylalanyl, Pro, pyro-Glu, Sar, Ser, or Thr at  
 30 position 1  
 31 <221> NAME/KEY: VARIANT  
 32 <222> LOCATION: (2)...(2)  
 33 <223> OTHER INFORMATION: Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,  
 34 or Ser at position 2  
 35 <221> NAME/KEY: VARIANT  
 36 <222> LOCATION: (3)...(3)  
 37 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,  
 38 Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,  
 39 or Cys at position 3  
 40 <221> NAME/KEY: VARIANT  
 41 <222> LOCATION: (4)...(4)  
 42 <223> OTHER INFORMATION: Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at  
 43 position 4  
 44 <221> NAME/KEY: VARIANT  
 45 <222> LOCATION: (5)...(5)  
 46 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,  
 47 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,  
 48 Nva, Octylgly, Orn, Phe(4-CH2OH), Pro, Ser, Thr,

BEST AVAILABLE COPY

## RAW SEQUENCE LISTING

DATE: 05/21/2001

PATENT APPLICATION: US/09/833,196

TIME: 12:14:40

Input Set: N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

```

49      Trp, Tyr, Pen, or Cys at position 5
50 <221> NAME/KEY: VARIANT
51 <222> LOCATION: (6)...(6)
52 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
53      Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
54      Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
55      at position 6
56 <221> NAME/KEY: VARIANT
57 <222> LOCATION: (6)...(6)
58 <223> OTHER INFORMATION: 6 Cont'd:
59      Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
60      Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
61      Tyr, Val, Pen, or Cys at position 6
62 <221> NAME/KEY: VARIANT
63 <222> LOCATION: (7)...(7)
64 <223> OTHER INFORMATION: Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly,
65      Hser, Ile, alloIle, Leu, Lys(Ac), Met, 1-Nal,
66      2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,
67      Val, Pen, or Cys at position 7
68 <221> NAME/KEY: VARIANT
69 <222> LOCATION: (8)...(8)
70 <223> OTHER INFORMATION: Xaa = Aminopyrimidinobutanoyl, Ala(3-guanidino),
71      Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],
72      Arg, arginyl(NGNG'diethyl), Cit, Cha(4-NIsp),
73      Gly[4-pip(N-amido)], at position 8
74 <221> NAME/KEY: VARIANT
75 <222> LOCATION: (8)...(8)
76 <223> OTHER INFORMATION: 8 Cont'd:
77      Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,
78      Orn(Isp), Orn(Nic), Orn(2-imidazo),
79      Phe(4-CH2NHisp), Phe(4-guanidino), or Phe(4-NIsp)
W--> 80      at position 8
81 <221> NAME/KEY: VARIANT
82 <222> LOCATION: (9)...(9)
83 <223> OTHER INFORMATION: Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile,
84      Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at
85      position 9.
86 <221> NAME/KEY: VARIANT
87 <222> LOCATION: (10)...(10)
88 <223> OTHER INFORMATION: Xaa = azaglycylamide, glycylamide,
89      glycylethylamide, sarcosylamide, serylamide at
90      position 10
91 <400> SEQUENCE: 1
W--> 92      Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
93          1             5             10
95 <210> SEQ ID NO: 2
96 <211> LENGTH: 9
97 <212> TYPE: PRT
98 <213> ORGANISM: Artificial Sequence

```

BEST AVAILABLE COPY

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

```

99 <220> FEATURE:
100 <223> OTHER INFORMATION: Antiangiogenetic peptide
101 <221> NAME/KEY: VARIANT
102 <222> LOCATION: (1)...(1)
103 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
104 <221> NAME/KEY: VARIANT
105 <222> LOCATION: (6)...(6)
106 <223> OTHER INFORMATION: Xaa = norvaline at position 6
107 <400> SEQUENCE: 2
W--> 108      Xaa Gly Val Ile Thr Xaa Ile Arg Pro
109          1           5
111 <210> SEQ ID NO: 3
112 <211> LENGTH: 9
113 <212> TYPE: PRT
114 <213> ORGANISM: Artificial Sequence
115 <220> FEATURE:
116 <223> OTHER INFORMATION: Antiangiogenetic peptide
117 <221> NAME/KEY: VARIANT
118 <222> LOCATION: (1)...(1)
119 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
120 <221> NAME/KEY: VARIANT
121 <222> LOCATION: (6)...(6)
122 <223> OTHER INFORMATION: Xaa = norvaline at position 6
123 <400> SEQUENCE: 3
W--> 124      Xaa Gly Val Gly Thr Xaa Ile Arg Pro
125          1           5
127 <210> SEQ ID NO: 4
128 <211> LENGTH: 9
129 <212> TYPE: PRT
130 <213> ORGANISM: Artificial Sequence
131 <220> FEATURE:
132 <223> OTHER INFORMATION: Antiangiogenetic peptide
133 <221> NAME/KEY: VARIANT
134 <222> LOCATION: (1)...(1)
135 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
136 <221> NAME/KEY: VARIANT
137 <222> LOCATION: (4)...(4)
138 <223> OTHER INFORMATION: Xaa = allo-isoleucyl at position 4
139 <221> NAME/KEY: VARIANT
140 <222> LOCATION: (6)...(6)
141 <223> OTHER INFORMATION: Xaa = norvaline at position 6
142 <400> SEQUENCE: 4
W--> 143      Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
144          1           5
146 <210> SEQ ID NO: 5
147 <211> LENGTH: 9
148 <212> TYPE: PRT
149 <213> ORGANISM: Artificial Sequence
150 <220> FEATURE:

```

REST AVAILABLE COPY

## RAW SEQUENCE LISTING

DATE: 05/21/2001

PATENT APPLICATION: US/09/833,196

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

151 <223> OTHER INFORMATION: Antiangiogenetic peptide  
 152 <221> NAME/KEY: VARIANT  
 153 <222> LOCATION: (1)...(1)  
 154 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1  
 155 <221> NAME/KEY: VARIANT  
 156 <222> LOCATION: (4)...(4)  
 157 <223> OTHER INFORMATION: Xaa = dehydroleucyl at position 4  
 158 <221> NAME/KEY: VARIANT  
 159 <222> LOCATION: (6)...(6)  
 160 <223> OTHER INFORMATION: Xaa = norvaline at position 6  
 161 <400> SEQUENCE: 5  
 W--> 162 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro  
 163 1 5  
 165 <210> SEQ ID NO: 6  
 166 <211> LENGTH: 11  
 167 <212> TYPE: PRT  
 168 <213> ORGANISM: Artificial Sequence  
 169 <220> FEATURE:  
 170 <223> OTHER INFORMATION: Antiangiogenetic Peptide  
 171 <221> NAME/KEY: VARIANT  
 172 <222> LOCATION: (1)...(1)  
 173 <223> OTHER INFORMATION: Xaa = R-(CH<sub>2</sub>)<sub>n</sub>-C(O)- where R is N-acetylamino at  
 174 position 1  
 175 <221> NAME/KEY: VARIANT  
 176 <222> LOCATION: (2)...(2)  
 177 <223> OTHER INFORMATION: Xaa = Sar at position 2  
 178 <221> NAME/KEY: VARIANT  
 179 <222> LOCATION: (5)...(5)  
 180 <223> OTHER INFORMATION: Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at  
 181 position 5  
 182 <221> NAME/KEY: VARIANT  
 183 <222> LOCATION: (6)...(6)  
 184 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,  
 185 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,  
 186 Nva, Octylgly, Orn, Phe(3-CH<sub>2</sub>OH), Pro, Ser, Thr,  
 187 Trp, Tyr, Pen or Cys at position 6  
 188 <221> NAME/KEY: VARIANT  
 189 <222> LOCATION: (7)...(7)  
 190 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,  
 191 Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,  
 192 Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),  
 193 at position 7  
 194 <221> NAME/KEY: VARIANT  
 195 <222> LOCATION: (7)...(7)  
 196 <223> OTHER INFORMATION: 7 Con'td:  
 197 Xaa = Met(O<sub>2</sub>), Met(O), Met, Nor, Nva, Octylgly,  
 198 Phe, Phe(4-CONH<sub>2</sub>), Propargylgly, Ser, Thr, Trp,  
 199 Tyr, Val, Pen, or Cys at position 7  
 200 <221> NAME/KEY: VARIANT

BEST AVAILABLE COPY

## RAW SEQUENCE LISTING

DATE: 05/21/2001

PATENT APPLICATION: US/09/833,196

TIME: 12:14:40

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

201 <222> LOCATION: (11)...(11)  
202 <223> OTHER INFORMATION: Xaa = Azaglycylamide, glycylamide,  
203 glycylethylamide, sarcosylamide, serylamide at  
204 position 11  
205 <400> SEQUENCE: 6  
W--> 206 Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa  
207 1 5 10

BEST AVAILABLE COPY

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/833,196

DATE: 05/21/2001

TIME: 12:14:41

Input Set : N:\Crf3\04272001\I833196.raw

Output Set: N:\CRF3\05212001\I833196.raw

L:80 M:259 W: Allowed number of lines exceeded, &lt;223&gt; Other Information:

L:92 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1

L:108 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2

L:124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3

L:143 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4

L:162 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5

L:206 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6

BEST AVAILABLE COPY